FLORENCE, Italy and NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline" ...

Study results demonstrated that in adult patients with blastic plasmacytoid dendritic cell neoplasm, the targeted therapy resulted in high response rates, particularly among treatment-naïve patients.

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has ...

FLORENCE, Italy, Nov. 13, 2020 /PRNewswire/ -- The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the Committee for Medicinal Products for Human ...

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. This is an ASCO Meeting Abstract from the 2019 ASCO ...

Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is an aggressive orphan hematologic ...

An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates ...

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I.

FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline" ...